Journal article

Targeting properties of an anti-CD16/anti-CD30 bispecific: antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall, B Catimel, EC Nice, A Mountain, A Rigopoulos, MW Brechbiel, M Pfreundschuh, AM Scott

CANCER IMMUNOLOGY IMMUNOTHERAPY | SPRINGER-VERLAG | Published : 2001

Abstract

Bispecific antibodies are currently being used in clinical trials in increasing numbers in the areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma. We have previously performed two clinical trials in patients with Hodgkin's disease with an anti-CD30/anti-CD16 bispecific antibody and demonstrated a 30% response rate in a cohort of patients otherwise resistant to standard therapeutic modalities. However, no surrogate marker could be defined in these trials indicative of optimal antibody dosing/scheduling or predictive for favorable response. In order to evaluate accurately the potential biodistribution properties of bispecific antibody in patients, we have pe..

View full abstract